Stock SNGX SOLIGENIX, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Soligenix, Inc.

Equities

SNGX

US8342235053

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-10 EDT 		5-day change 1st Jan Change
0.3989 USD -1.75% Intraday chart for Soligenix, Inc. -1.38% -47.32%
04-25 Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa CI
04-15 Sector Update: Health Care Stocks Softer Late Afternoon MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
PR
Soligenix to Present at Upcoming Conferences
PR
Soligenix Announces Pricing of $4.75 Million Public Offering
PR
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
PR
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
PR
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
PR
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
PR
Soligenix Announces Formation of Beh et s Disease Medical Advisory Board
AQ
Soligenix to Present at The Microcap Conference
PR
FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behcet's Disease
AQ
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
PR
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
PR
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
PR
Soligenix, Inc. - HyBryte Use in Early-Stage Cutaneous T-Cell Lymphoma, Published in Frontiers in Drug Discovery
AQ
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
PR
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
PR
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
AQ
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
PR
Soligenix Announces Recent Accomplishments And Third Quarter 2023 Financial Results
PR
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SNGX Stock
  4. News Soligenix, Inc.
  5. Press Releases
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW